MC
LUNG icon

Maverick Capital’s Pulmonx LUNG Stock Holding History

Maverick Capital’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,245
Closed -$980K – 505
2021
Q3 		$980K Sell
27,245
-7,557
-22% -$297K 0.01% 320
2021
Q2 		$1.53M Buy
34,802
+10,353
+42% +$451K 0.01% 196
2021
Q1 		$1.12M Buy
+24,449
New +$1.4M 0.01% 229

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Maverick Capital's LUNG Position: Q4 2021 in Review

Maverick Capital sold out of Pulmonx (LUNG) in Q4 2021, closing a stake of 27,245 shares — an estimated $980K sold.

Maverick Capital first reported a position in LUNG in Q1 2021 and held it in 3 quarters. The position peaked at $1.53M in Q2 2021. 114 funds tracked by Wall St. Rank hold LUNG as of Q4 2021.

  • Maverick Capital reported no remaining Pulmonx position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 27,245 Pulmonx shares in Q4 2021, an estimated $980K.
  • Maverick Capital first reported a position in Pulmonx in Q1 2021 and held it in 3 quarters.
  • Maverick Capital's Pulmonx position peaked at $1.53M in Q2 2021.
  • 114 funds tracked by Wall St. Rank held Pulmonx as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.